MIPOL1-ETV1 gene rearrangements
Compositions and methods associated with recurrent MIPOL1-ETV1 genetic rearrangements that are useful for cancer diagnosis and therapy are disclosed.
1. A method for detecting a MIPOL1-ETV1 genetic rearrangement in a biological sample, the method comprising:
a) contacting a biological sample with a probe directly labeled with a detectable label and comprising a sequence that hybridizes specifically to a junction at which an ETV1 gene is inserted into a MIPOL1 gene; and
b) detecting the MIPOL1-ETV1 genetic rearrangement by detecting hybridization of said probe to a nucleic acid comprising said junction.
2. The method of claim 1 , wherein the nucleic acid comprises a chromosomal rearrangement of genomic DNA that comprises MIPOL1 genetic material and ETV1 genetic material in the same genomic region.
3. The method of claim 1 further comprising identifying an individual from whom the biological sample was derived as having or at risk of having prostate cancer when hybridization of said probe to said nucleic acid is detected in the biological sample.
4. The method of claim 1 , wherein detecting hybridization of said probe to said nucleic acid comprising said junction comprises use of a nucleic acid hybridization technique selected from the group consisting of: in situ hybridization (ISH), analysis of hybridization to a microarray of probes, and Southern blot analysis.
5. The method of claim 1 , wherein said nucleic acid is a product of a nucleic acid amplification method.
6. The method of claim 5 , wherein the nucleic acid amplification method used is selected from the group consisting of: polymerase chain reaction (PCR), reverse transcription polymerase chain reaction (RT-PCR), transcription-mediated amplification (TMA), ligase chain reaction (LCR), strand displacement amplification (SDA), and nucleic acid sequence based amplification (NASBA).
7. The method of claim 1 , wherein the biological sample is selected from the group consisting of tissue, blood, plasma, serum, urine, urine supernatant, urine cell pellet, semen, prostatic secretions, and prostate cells.
8. A composition for detecting a MIPOL1-ETV1 genetic rearrangement associated with prostate cancer comprising a probe directly labeled with a detectable label and comprising a sequence that hybridizes specifically to a junction at which an ETV1 gene is inserted into a MIPOL1 gene.
9. A detection assay composition for detecting a MIPOL1-ETV1 genetic rearrangement associated with prostate cancer, said detection assay composition comprising an isolated nucleic acid comprising a MIPOL1-ETV1 genetic rearrangement and:
a) a probe directly labeled with a detectable label and specifically hybridized to a junction at which an ETV1 gene is inserted into a MIPOL1 gene in the MIPOL1-ETV1 genetic rearrangement;
b) a first probe directly labeled with a detectable label and specifically hybridized to a MIPOL1 gene in the MIPOL1-ETV1 genetic rearrangement and a second probe directly labeled with a detectable label and specifically hybridized to an ETV1 gene in the MIPOL1-ETV1 genetic rearrangement; or
c) a first amplification oligonucleotide specifically hybridized to a MIPOL1 gene in the MIPOL1-ETV1 genetic rearrangement, a second amplification oligonucleotide specifically hybridized to an ETV1 gene in the MIPOL1-ETV1 genetic rearrangement, and a probe directly labeled with a detectable label for detecting an amplified product.
10. The detection assay composition of claim 9 , wherein said detection assay comprises the probe specifically hybridized to a junction at which an ETV1 gene is inserted into a MIPOL1 gene in the MIPOL1-ETV1 genetic rearrangement.
11. The detection assay composition of claim 9 , wherein the detectable label is selected from the group consisting of a chemiluminescent label and a fluorescent label.